Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Our experts agree that there are many simple ways to minimize the chances of breast cancer returning. Adopting a healthy ...

The results of a clinical trial published last month targeted breast cancer "sleeper cells," which are cells that break away ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.

From blood tests that predict recurrence to smarter, less invasive treatments, 2025 is delivering real hope—especially for ...

A newly developed antibody that restricts the growth of treatment-resistant breast cancers offers new hope for patients. It ...

Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types -- N17350 targets a cancer vulnerability, via the ...

A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

One participant in the trial, Illeana Casiano-Vazquez, was treated for triple-negative breast cancer, an aggressive cancer with high odds of recurrence. Her chance of the cancer returning within five ...